Risk of colorectal cancer and cancer-related mortality in type 2 diabetes patients treated with metformin, SGLT-2 inhibitors, or their combination

Xianhua Mao; Ka-Shing Cheung; Jing-Tong Tan; Lung-Yi Mak; Chi-Ho Lee; Ho Ming Cheng; Rex Wan-Hin Hui; Esther Wai Yin Chan; Philip Leung-Ho Yu; Man-Fung Yuen; Wai K Leung; Wai-Kay Seto

doi:10.1002/cac2.70028

Cancer Communications ›› 2025, Vol. 45 ›› Issue (7) : 880 -883. DOI: 10.1002/cac2.70028

LETTER TO THE JOURNAL

Risk of colorectal cancer and cancer-related mortality in type 2 diabetes patients treated with metformin, SGLT-2 inhibitors, or their combination

Author information +

History +

PDF

Cite this article

Download citation ▾

Xianhua Mao, Ka-Shing Cheung, Jing-Tong Tan, Lung-Yi Mak, Chi-Ho Lee, Ho Ming Cheng, Rex Wan-Hin Hui, Esther Wai Yin Chan, Philip Leung-Ho Yu, Man-Fung Yuen, Wai K Leung, Wai-Kay Seto. Risk of colorectal cancer and cancer-related mortality in type 2 diabetes patients treated with metformin, SGLT-2 inhibitors, or their combination. Cancer Communications, 2025, 45(7): 880-883 DOI:10.1002/cac2.70028

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet. 2019; 394(10207): 1467-1480.

[2]	Lawler T, Walts ZL, Steinwandel M, Lipworth L, Murff HJ, Zheng W. Type 2 Diabetes and Colorectal Cancer Risk. JAMA Netw Open. 2023; 6(11): e2343333.

[3]	Liang PS, Shaukat A, Crockett SD. AGA Clinical Practice Update on Chemoprevention for Colorectal Neoplasia: Expert Review. Clin Gastroenterol Hepatol. 2021; 19(7): 1327-1336.

[4]

Home PD, Kahn SE, Jones NP, Noronha D, Beck-Nielsen H, Viberti G. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia. 2010; 53(9): 1838-1845.

[5]	Chan RNC, Chan RNF, Chou OHI, Tse G, Lee S. Lower risks of incident colorectal cancer in SGLT2i users compared to DPP4i users: A propensity score-matched study with competing risk analysis. Eur J Intern Med. 2023; 110: 125-127.

[6]	Sung HL, Hung CY, Tung YC, Lin CC, Tsai TH, Huang KH. Comparison between sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase 4 inhibitors on the risk of incident cancer in patients with diabetes mellitus: A real-world evidence study. Diabetes Metab Res Rev. 2024; 40(3): e3784.

[7]	Mao X, Cheung KS, Tan JT, Mak LY, Lee CH, Chiang CL. Optimal glycaemic control and the reduced risk of colorectal adenoma and cancer in patients with diabetes: a population-based cohort study. Gut. 2024; 73(8): 1313-1320.

[8]	Okada J, Yamada E, Saito T, Yokoo H, Osaki A, Shimoda Y, et al. Dapagliflozin Inhibits Cell Adhesion to Collagen I and IV and Increases Ectodomain Proteolytic Cleavage of DDR1 by Increasing ADAM10 Activity. Molecules. 2020; 25(3): 495.

[9]	Dutka M, Bobiński R, Francuz T, Garczorz W, Zimmer K, Ilczak T, et al. SGLT-2 Inhibitors in Cancer Treatment-Mechanisms of Action and Emerging New Perspectives. Cancers (Basel). 2022; 14(23): 5811.

[10]	Kogot-Levin A, Riahi Y, Abramovich I, Mosenzon O, Agranovich B, Kadosh L, et al. Mapping the metabolic reprogramming induced by sodium-glucose cotransporter 2 inhibition. JCI Insight. 2023; 8(7): e164296.